| Chhabra Medical Corporation Pc | |
|
6375 Us Highway 6 Portage IN 46368-5111 | |
| (219) 762-3196 | |
| (219) 763-6438 |
| Full Name | Chhabra Medical Corporation Pc |
|---|---|
| Speciality | Family Medicine |
| Location | 6375 Us Highway 6, Portage, Indiana |
| Authorized Official Name and Position | Bhupindar Chhabra (PRESIDENT) |
| Authorized Official Contact | 2197623196 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Chhabra Medical Corporation Pc 6375 Us Highway 6 Portage IN 46368-5111 Ph: (219) 762-3196 | Chhabra Medical Corporation Pc 6375 Us Highway 6 Portage IN 46368-5111 Ph: (219) 762-3196 |
| NPI Number | 1518960988 |
|---|---|
| Provider Enumeration Date | 05/31/2005 |
| Last Update Date | 11/28/2023 |
| Medicare PECOS PAC ID | 8729045786 |
|---|---|
| Medicare Enrollment ID | O20041213000106 |
News Archive
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, today announced the acquisition of Eon Surgical, Ltd., a late stage development company that has advanced a minimally invasive microlaparoscopy surgical platform technology designed to enhance surgeons' ability to perform scarless surgery while producing better patient outcomes.
LYSOGENE announces the authorization by AFSSAPS (the French Agency for the Safety of Health Products) and by the Ethical Review Board of SAF-301, its leading intra-cerebral gene therapy phase I/II clinical trial aiming at treating Sanfilippo Type A Syndrome.
NYU Langone Medical Center announced today that it is the first medical center in the Northeast to use PatientSecure™ - a cutting-edge biometric technology - to identify patients. Utilizing near infrared light to map an image of the blood-flow pattern through the veins in a person's palm, the digital palm image is converted into a unique patient identifier that interfaces with the medical center's electronic health record system.
Scientists at Galileo Pharmaceuticals, Inc. have demonstrated a direct relationship between inflammation and glucose levels. Through its recently established metabolic disease program, Galileo confirmed in preclinical models that inhibiting lipoxygenases, known mediators of inflammatory response, significantly lowers blood glucose levels in animal models of diabetes.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518960988 | NPI | - | NPPES |
| 200140300A | Medicaid | IN | |
| 300024894 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 50003261A (Indiana) | Secondary |
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Manjeet Geeta |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1811949035 PECOS PAC ID: 5890717011 Enrollment ID: I20060705000142 |
News Archive
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, today announced the acquisition of Eon Surgical, Ltd., a late stage development company that has advanced a minimally invasive microlaparoscopy surgical platform technology designed to enhance surgeons' ability to perform scarless surgery while producing better patient outcomes.
LYSOGENE announces the authorization by AFSSAPS (the French Agency for the Safety of Health Products) and by the Ethical Review Board of SAF-301, its leading intra-cerebral gene therapy phase I/II clinical trial aiming at treating Sanfilippo Type A Syndrome.
NYU Langone Medical Center announced today that it is the first medical center in the Northeast to use PatientSecure™ - a cutting-edge biometric technology - to identify patients. Utilizing near infrared light to map an image of the blood-flow pattern through the veins in a person's palm, the digital palm image is converted into a unique patient identifier that interfaces with the medical center's electronic health record system.
Scientists at Galileo Pharmaceuticals, Inc. have demonstrated a direct relationship between inflammation and glucose levels. Through its recently established metabolic disease program, Galileo confirmed in preclinical models that inhibiting lipoxygenases, known mediators of inflammatory response, significantly lowers blood glucose levels in animal models of diabetes.
› Verified 6 days ago
| Provider Name | Debra L Drescher |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407939895 PECOS PAC ID: 1355408709 Enrollment ID: I20090330000391 |
News Archive
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, today announced the acquisition of Eon Surgical, Ltd., a late stage development company that has advanced a minimally invasive microlaparoscopy surgical platform technology designed to enhance surgeons' ability to perform scarless surgery while producing better patient outcomes.
LYSOGENE announces the authorization by AFSSAPS (the French Agency for the Safety of Health Products) and by the Ethical Review Board of SAF-301, its leading intra-cerebral gene therapy phase I/II clinical trial aiming at treating Sanfilippo Type A Syndrome.
NYU Langone Medical Center announced today that it is the first medical center in the Northeast to use PatientSecure™ - a cutting-edge biometric technology - to identify patients. Utilizing near infrared light to map an image of the blood-flow pattern through the veins in a person's palm, the digital palm image is converted into a unique patient identifier that interfaces with the medical center's electronic health record system.
Scientists at Galileo Pharmaceuticals, Inc. have demonstrated a direct relationship between inflammation and glucose levels. Through its recently established metabolic disease program, Galileo confirmed in preclinical models that inhibiting lipoxygenases, known mediators of inflammatory response, significantly lowers blood glucose levels in animal models of diabetes.
› Verified 6 days ago
| Provider Name | Suzanne Meeks |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1679746044 PECOS PAC ID: 5193854107 Enrollment ID: I20100601000827 |
News Archive
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, today announced the acquisition of Eon Surgical, Ltd., a late stage development company that has advanced a minimally invasive microlaparoscopy surgical platform technology designed to enhance surgeons' ability to perform scarless surgery while producing better patient outcomes.
LYSOGENE announces the authorization by AFSSAPS (the French Agency for the Safety of Health Products) and by the Ethical Review Board of SAF-301, its leading intra-cerebral gene therapy phase I/II clinical trial aiming at treating Sanfilippo Type A Syndrome.
NYU Langone Medical Center announced today that it is the first medical center in the Northeast to use PatientSecure™ - a cutting-edge biometric technology - to identify patients. Utilizing near infrared light to map an image of the blood-flow pattern through the veins in a person's palm, the digital palm image is converted into a unique patient identifier that interfaces with the medical center's electronic health record system.
Scientists at Galileo Pharmaceuticals, Inc. have demonstrated a direct relationship between inflammation and glucose levels. Through its recently established metabolic disease program, Galileo confirmed in preclinical models that inhibiting lipoxygenases, known mediators of inflammatory response, significantly lowers blood glucose levels in animal models of diabetes.
› Verified 6 days ago
| Provider Name | Katrina M Kozub |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508166547 PECOS PAC ID: 3971771130 Enrollment ID: I20110714000521 |
News Archive
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, today announced the acquisition of Eon Surgical, Ltd., a late stage development company that has advanced a minimally invasive microlaparoscopy surgical platform technology designed to enhance surgeons' ability to perform scarless surgery while producing better patient outcomes.
LYSOGENE announces the authorization by AFSSAPS (the French Agency for the Safety of Health Products) and by the Ethical Review Board of SAF-301, its leading intra-cerebral gene therapy phase I/II clinical trial aiming at treating Sanfilippo Type A Syndrome.
NYU Langone Medical Center announced today that it is the first medical center in the Northeast to use PatientSecure™ - a cutting-edge biometric technology - to identify patients. Utilizing near infrared light to map an image of the blood-flow pattern through the veins in a person's palm, the digital palm image is converted into a unique patient identifier that interfaces with the medical center's electronic health record system.
Scientists at Galileo Pharmaceuticals, Inc. have demonstrated a direct relationship between inflammation and glucose levels. Through its recently established metabolic disease program, Galileo confirmed in preclinical models that inhibiting lipoxygenases, known mediators of inflammatory response, significantly lowers blood glucose levels in animal models of diabetes.
› Verified 6 days ago
| Provider Name | Samantha Wojcik |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225481013 PECOS PAC ID: 6608157920 Enrollment ID: I20161228002334 |
News Archive
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, today announced the acquisition of Eon Surgical, Ltd., a late stage development company that has advanced a minimally invasive microlaparoscopy surgical platform technology designed to enhance surgeons' ability to perform scarless surgery while producing better patient outcomes.
LYSOGENE announces the authorization by AFSSAPS (the French Agency for the Safety of Health Products) and by the Ethical Review Board of SAF-301, its leading intra-cerebral gene therapy phase I/II clinical trial aiming at treating Sanfilippo Type A Syndrome.
NYU Langone Medical Center announced today that it is the first medical center in the Northeast to use PatientSecure™ - a cutting-edge biometric technology - to identify patients. Utilizing near infrared light to map an image of the blood-flow pattern through the veins in a person's palm, the digital palm image is converted into a unique patient identifier that interfaces with the medical center's electronic health record system.
Scientists at Galileo Pharmaceuticals, Inc. have demonstrated a direct relationship between inflammation and glucose levels. Through its recently established metabolic disease program, Galileo confirmed in preclinical models that inhibiting lipoxygenases, known mediators of inflammatory response, significantly lowers blood glucose levels in animal models of diabetes.
› Verified 6 days ago
| Provider Name | Laura Cannon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235634221 PECOS PAC ID: 1153670591 Enrollment ID: I20180820000193 |
News Archive
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, today announced the acquisition of Eon Surgical, Ltd., a late stage development company that has advanced a minimally invasive microlaparoscopy surgical platform technology designed to enhance surgeons' ability to perform scarless surgery while producing better patient outcomes.
LYSOGENE announces the authorization by AFSSAPS (the French Agency for the Safety of Health Products) and by the Ethical Review Board of SAF-301, its leading intra-cerebral gene therapy phase I/II clinical trial aiming at treating Sanfilippo Type A Syndrome.
NYU Langone Medical Center announced today that it is the first medical center in the Northeast to use PatientSecure™ - a cutting-edge biometric technology - to identify patients. Utilizing near infrared light to map an image of the blood-flow pattern through the veins in a person's palm, the digital palm image is converted into a unique patient identifier that interfaces with the medical center's electronic health record system.
Scientists at Galileo Pharmaceuticals, Inc. have demonstrated a direct relationship between inflammation and glucose levels. Through its recently established metabolic disease program, Galileo confirmed in preclinical models that inhibiting lipoxygenases, known mediators of inflammatory response, significantly lowers blood glucose levels in animal models of diabetes.
› Verified 6 days ago
News Archive
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, today announced the acquisition of Eon Surgical, Ltd., a late stage development company that has advanced a minimally invasive microlaparoscopy surgical platform technology designed to enhance surgeons' ability to perform scarless surgery while producing better patient outcomes.
LYSOGENE announces the authorization by AFSSAPS (the French Agency for the Safety of Health Products) and by the Ethical Review Board of SAF-301, its leading intra-cerebral gene therapy phase I/II clinical trial aiming at treating Sanfilippo Type A Syndrome.
NYU Langone Medical Center announced today that it is the first medical center in the Northeast to use PatientSecure™ - a cutting-edge biometric technology - to identify patients. Utilizing near infrared light to map an image of the blood-flow pattern through the veins in a person's palm, the digital palm image is converted into a unique patient identifier that interfaces with the medical center's electronic health record system.
Scientists at Galileo Pharmaceuticals, Inc. have demonstrated a direct relationship between inflammation and glucose levels. Through its recently established metabolic disease program, Galileo confirmed in preclinical models that inhibiting lipoxygenases, known mediators of inflammatory response, significantly lowers blood glucose levels in animal models of diabetes.
› Verified 6 days ago
Primary Care Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3125 Willowcreek Road, Portage, IN 46368 Phone: 219-762-3175 Fax: 219-763-3092 | |
Kota Medical Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3630 Willowcreek Rd, Portage, IN 46368 Phone: 219-759-5812 Fax: 219-759-5890 | |
Willow Creek Medical Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3156 Willowcreek Rd, Portage, IN 46368 Phone: 219-762-4999 Fax: 219-762-2288 | |
New Beginnings Suboxone Treatment, Llc Corp Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2640 Hamstrom Rd, Portage, IN 46368 Phone: 219-762-4423 | |
Ranga Kota Md, Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3630 Willowcreek Rd, Portage, IN 46368 Phone: 219-759-5812 | |
Healtheaccess Clinics L.l.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 6615 S Boundary Rd, Portage, IN 46368 Phone: 219-787-8662 | |
Internal Medicine,geriatrics And Oncology Group, P.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2640 Hamstrom Rd, Portage, IN 46368 Phone: 219-762-9523 Fax: 219-763-3120 |